Micromet, Inc. (NASDAQ:MITI)

JPG101 (52.92) Submitted: 8/18/2008 10:11:35 AM : Start Price: $5.88 MITI Score: +82.39

Small German biotech company working on BiTE (Bispecific T Cell Engagers) technology. They published a phase I study on the use of a CD3 and CD19 small partial antibody 'mix'. The NHL patients treated in this study had very very impressive response rates with extremly low doses in this early phase I study. Long term infusions were used are very logical in the context of this relatively small molecule. The clinical side effects are what you would expect and almost hope for to signal immun activation.

Very impressive technology that might solve the BiTE problems with smaller partial antibodies.

Exciting: very very exciting! I'm in big time. Just to bad I haden't heard about them a few months ago. Just hard to follow so many small biotech companies. Hope their stock price goes down a bit so I could get more of this possibly revolutionary company.

This is one of those rare tech companies that changes all the rule or fails quickly if their technology doesn't work. It's a binary proposition with a risk/ reward I find very positive. Time will tell...